Mydecine Innovations Group (NEO: MYCO) (OTCMKTS: MYCOF) Co-Founder and CEO Joshua Bartch tells Proactive the group has identified its first four novel drug candidates to potentially treat mental illnesses. Bartch explains how each drug, which include psychedelic compounds derived from psilocybin and MDMA, will be used within current and upcoming clinical trials in the US and in Canada. Bartch also talked about how the group's spinoff of its cannabis assets will help it to up-list in London and in New York.
Mydecine Innovations Group identifies its first four psychedelic-related novel drug candidates
